Skip to content

The Oligonucleotide Therapeutics Society is Pleased to Announce the 2023 Annual Meeting in Barcelona, Spain

Oligonucleotide Therapeutics Society 3 mins read

SAN DIEGO, CA / ACCESSWIRE / June 28, 2023 / The Oligonucleotide Therapeutics Society (OTS) is excited to bring together those in the field of oligonucleotide therapeutics for its 19th Annual Oligo Meeting. Anyone interested in oligonucleotide therapeutics is welcome to join the event, which will be held virtually and in person on Oct. 22-25, 2023, in Barcelona, Spain.

Oligonucleotide Therapeutics Society, Wednesday, June 28, 2023, Press release picture

OTS is an open, nonprofit forum that fosters academic and industry-based research and the development of oligonucleotide therapeutics. At this year's meeting, leaders from across the globe will present alongside students, covering topics ranging from antisense, siRNA, immunostimulatory and aptamer applications, RNA/DNA editing, mRNA therapeutics, and basic RNA research.

This year's keynote speaker will be David Liu, PhD, from the Broad Institute of Harvard and MIT. Liu is known for inventing base editing, a tool for precisely modifying DNA, as well as prime editing, PACE and DNA-templated synthesis - technologies used by thousands of labs worldwide. His many achievements include being elected to the U.S. National Academy of Sciences, the U.S. National Academy of Medicine, and the American Association for the Advancement of Science. Liu has published over 225 papers and is the inventor of over 90 issued U.S. patents.

OTS has the privilege of presenting its Lifetime Achievement Awards, with the 2022 Award going to Sudhir Agrawal, D. Phil, a key player in the discovery and development of RNA therapeutics and the co-inventor of over 400 patents worldwide. As president and founder of ARNAY Sciences LLC, his company's pioneering publications helped establish antisense as a new drug discovery platform and have contributed to critical discoveries in gapmer antisense and exon skipping.

The 2023 Lifetime Achievement Award will be presented to Cy Stein, MD, PhD, who has over three decades of experience treating prostate and genitourinary cancer patients. Throughout his career, Stein has mixed his love for science with his passion for caring for patients and hopes to continue doing so for many years to come. His four decades of scientific research have primarily been dedicated to developing novel anti-cancer drugs.

As the area of oligonucleotide therapeutics continues to thrive and evolve, OTS will continue to support this vital work, with its annual meeting serving as a dialogue and discussion among industry, academia, and health authorities to educate and share their progress. Currently, over 100 oligonucleotide treatments are in development for common and rare conditions, including cancer and Alzheimer's disease, and several have received regulatory approval.

OTS looks forward to seeing attendees either in person or online. In-person registration will be closed at 750 delegates, so early registration is recommended for those wishing to attend in person.

Anyone interested in attending can view more information at or register here.

Media Contact:

Geri Beaty
Phone: (619) 795-9458

Contact Information:

Geri Beaty
Media Contact
(619) 795-9458

SOURCE: Oligonucleotide Therapeutics Society


View source version on

More from this category

  • Biotechnology
  • 28/05/2024
  • 20:07
The BioMed X Institute

BioMed X Institute and Boehringer Ingelheim Successfully Complete Schizophrenia Research Project

The research of BioMed X team EPD - Early Intervention in Psychiatric Diseases - has shed light on the molecular mechanisms underlying white matter deficits in schizophrenia.HEIDELBERG, GERMANY / ACCESSWIRE / May 28, 2024 / German independent research institute BioMed X announces the successful completion of its second neuroscience project in partnership with Boehringer Ingelheim in the field of psychiatric disorders. The data resulting from this project have been acquired by Boehringer Ingelheim, where this research will be continued, potentially paving the way for novel therapies. This research project was launched in 2020 at the BioMed X Institute in Heidelberg…

  • Biotechnology, Medical Health Aged Care
  • 24/05/2024
  • 10:53
Neuroscience Research Australia

NeuRA CEO elected as 2024 Fellow of the Australian Academy of Science

Scientia Professor Matthew Kiernan AM CEO at Neuroscience Research Australia has been elected as a 2024 Fellow of the Australian Academy of Science,joining the…

  • Contains:
  • Biotechnology, Science
  • 23/05/2024
  • 07:49
Brandon Capital

Up to $5 million In Funding Available for Dementia and Cognitive Decline Innovations Through CUREator+

23 May 2024 Melbourne: The CUREator+ Dementia and Cognitive Decline incubator program, a partnership between Brandon BioCatalyst, ANDHealth and Dementia Australia, has opened its first funding round. Companies pioneering innovative health technologies to enhance the lives of individuals affected by dementia and cognitive decline are set to receive up to $5 million per project in non-dilutive project funding, a substantial boost for their innovative solutions. Funded by the Federal Government’s $20 billion Medical Research Future Fund (MRFF), the program aims to support the development of novel approaches, spanning therapeutics, diagnostics, assistive and medical devices and digital health technologies, that will…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.